StemCell Therapy

Ligand Pharmaceuticals Inc. (LGND) is near the top in its industry group according to InvestorsObserver. LGND gets an overall rating of 74. That means it scores higher than 74 percent of stocks. Ligand Pharmaceuticals Inc. gets a 85 rank in the Biotechnology industry. Biotechnology is number 13 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Ligand Pharmaceuticals Inc. (LGND) stock has risen 3.84% while the S&P 500 is unmoved 0% as of 10:51 AM on Friday, Jul 10. LGND has risen $4.31 from the previous closing price of $112.21 on volume of 83,931 shares. Over the past year the S&P 500 is up 5.07% while LGND has risen 1.69%. LGND lost -$3.44 per share the over the last 12 months.

To screen for more stocks like LGND click here.

See the article here:
Does Ligand Pharmaceuticals Inc. (LGND) Stock Beat its Rivals in Biotechnology? - InvestorsObserver

This entry was posted on July 10, 2020 at 3:46 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |